Navigation Links
Upsher-Smith Announces Milestone in Development of CNS Strategy
Date:12/3/2009

MAPLE GROVE, Minn., Dec. 3 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced the next phase of its strategic plan for central nervous system (CNS) diseases with USL255 (extended release topiramate), an internally developed program for the management of epilepsy. USL255 is being developed with Upsher-Smith's proprietary formulation technology and will enter a phase III clinical trial in early 2010 for the adjunctive treatment of epilepsy patients with partial onset seizures. USL255 is designed to provide convenient once daily dosing and reduce fluctuations in topiramate blood levels observed with currently available topiramate options.

"Upsher-Smith's goal is to build our leadership position in the CNS field through three complementary strategies including: alliances and co-development agreements; leveraging development of our core competency in formulation development; and actively pursuing licensing and acquisitions," said Mark Evenstad, President of Upsher-Smith.

The USL255 program for epilepsy builds on Upsher-Smith's other CNS program, PRX1 for the symptomatic treatment of Parkinson's disease. PRX1 is a co-development program with Proximagen Neuroscience, a biopharmaceutical company focused on CNS diseases. In July 2008, Upsher-Smith entered into a worldwide licensing agreement covering the development and commercialization of Proximagen's proprietary PRX1 program.

"The clinical development of USL255 and the PRX1 program with Proximagen are in line with Upsher-Smith's vision to become a leader in providing therapies that empower people suffering from CNS diseases to lead healthy, productive lives," said Evenstad. "These two milestones demonstrate our core competencies and commitment to bringing the highest quality pharmaceuticals to patients for more than eight decades."

About Epilepsy and Parkinson's Disease

Epilepsy is a neurological condition that produces seizures affecting a variety of mental and physical functions. Almost three million people in the U.S. have some form of active epilepsy with about 200,000 new cases of epilepsy diagnosed each year.[1] Parkinson's disease is a chronic, progressive neurodegenerative disease that causes impairment in motor function, as well as many non-motor complications throughout the various stages of the disease. As many as 1 million people in the U.S. suffer from Parkinson's disease, with 1 in 100 people over the age of 60 affected. [2]

About Upsher-Smith

Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit www.upsher-smith.com.

Source:

[1]. Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/about/. Accessed on November 18, 2009

[2]. National Parkinson Foundation. Available at: http://www.parkinson.org/Page.aspx?pid=225. Accessed on November 18, 2009

SOURCE Upsher-Smith Laboratories, Inc.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
2. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
4. Varian, Inc. Announces Form 10-K Filing
5. Jupiter Medical Center Announces New High-Definition MRI System
6. TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois
7. Cardio Vascular Medical Device Announces Forward Stock Split
8. PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share
9. Clarient Announces CFO Transition Plan
10. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
11. AMT Announces Management Changes in Light of Refocused Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):